NEW YORK (GenomeWeb) – VolitionRx announced today that it has received CE marking for two of its blood-based diagnostic assays for colorectal cancer.

The tests, NuQ V001 and NuQ T003, are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features such as histone modifications and variations, DNA methylation patterns, and nucleosome-protein adducts. Last September, the company received CE marking for the NuQ X001S biomarker assay for colorectal cancer detection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.